Jurisdiction, Amgen

Third Circuit Holds That Granting Discovery Under Section 1782 Is Not a “Final” Judgment

Goodwin on 6/16/2025

The U.S. Court of Appeals for the Third Circuit recently issued an opinion holding that when a district court has ordered discovery under 28 U.S.C. § 1782, but has not yet conclusively defined the scope of that discovery, the...more

The Supreme Court Update - May 18, 2023

Dorsey & Whitney LLP on 5/19/2023

Today, the Supreme Court of the United States issued six decisions: Amgen Inc. v. Sanofi, No. 21-757: This case addressed the Patent Act’s “enablement” requirement—the provision that requires a patent applicant to describe...more

Genentech Moves To Dismiss Amgen’s California Bevacizumab DJ Action

Goodwin on 11/21/2017

We previously reported on Amgen’s complaint in the Central District of California seeking a declaratory judgment that 27 Genentech patents are not infringed by Genentech’s bevacizumab biosimilar (Mvasi®). On November 15,...more

Hospira Files Responsive Appeal Brief in Amgen v. Hospira Litigation

Goodwin on 11/4/2016

As we previously reported, Amgen filed an appeal brief challenging the district court’s resolution of its discovery dispute with Hospira and addressing the issue of whether the Federal Circuit had jurisdiction to hear the...more

Federal Circuit Patent Updates - July 2016 #2

WilmerHale on 7/21/2016

WBIP, LLC v. Kohler Co. (No. 2015-1038, -1044, 7/19/16) (Moore, O'Malley, Chen) - Moore, J. Affirming denial of JMOL that patent was invalid as obvious and lacked an adequate written description, affirming finding of...more

Recent Supreme Court Rulings on Class Actions

King & Spalding on 10/4/2013

The Supreme Court continued to focus on class action litigation during this term, handing down a number of significant rulings relating to jurisdiction, class certification, and arbitration of putative class claims. The many...more